CYP51-IN-32 

CYP51-IN-32 is an antifungal agent with an IC₅₀ of 0.331 μM against CYP51 of Candida albicans. CYP51-IN-32 releases hydrogen sulfide (H₂S) and inhibits hyphal formation and biofilm development of Candida albicans. CYP51-IN-32 can be formulated into PEG-based nanovesicles. CYP51-IN-32 is applicable to the research of Candida albicans infection^[1].

CYP51-IN-32 (Compound 3j) (PEG-niosome-formulated) potently inhibits Candida albicans growth with an MIC of 4.68 μg/mL^[1].
CYP51-IN-32's antifungal activity against Candida albicans is reduced when H₂S is scavenged by 1.5 mg/mL MgO, with its MIC rising to 32 μg/mL^[1].
CYP51-IN-32 robustly inhibits Candida albicans hyphal formation, maintaining the fungus in its unicellular yeast form^[1].
CYP51-IN-32 inhibits Candida albicans biofilm formation by 60% at a concentration of 0.0005 mg/mL^[1].
CYP51-IN-32 has an IC₅₀ of 65.73 μg/mL against WS-1 human skin fibroblasts, resulting in a selectivity index of ~14.0 relative to its antifungal MIC against Candida albicans^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

390.95

C₁₉H₁₉ClN₂OS₂

205251-67-8

O=C(C1=CC=C(Cl)C=C1)CSC(N(CC2)CCN2C3=CC=CC=C3)=S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sadiq GM, et al. Phenylpiperazine/dithioates as novel H₂S donors: design, synthesis, H₂S release, formulation as PEG-niosomes and antifungal activity against Candida albicans. Bioorg Chem. 2026;170:109494.  [Content Brief]